Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04637503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

StatusNot Yet Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Jun 1, 2026 to Dec 31, 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Study description expanded, about 66 words
    • Site details revised
    v4
  2. Study sites: 3 to 1v3
  3. Primary completion date: Nov 19, 2020 to Dec 31, 2029v2 Show 4 more changesShow less
    • Start date changed from estimate of Nov 18, 2020 to Jun 1, 2026
    • Study sites: 4 to 3
    • Study completion date: Dec 31, 2023 to Dec 31, 2030
    • Collaborators shortened, about 3 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB). Another goal of the study is to understand the function of the multi-CAR-T cells and their persistency in the patients.
Trial Details
NCT Number NCT04637503
Lead Sponsor Shenzhen Geno-Immune Medical Institute
Conditions
(from sponsor)		 Neuroblastoma
Related terms Gaucher Disease, Neuroblastoma
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov